Figure 2. rTMS’s cumulative effects on reversing frontal alpha asymmetry (FAA).

FAA of rTMS responders (in red color) and non-responders (in blue color) showed no difference from baseline (W0) to the end of the 1^st week (W1) and the 2^nd week (W2) after initiation of rTMS. In both groups, rTMS decreased FAA in a dose-dependent manner from W0 to W2, despite lack of statistical significance. During the follow-up period from the end of W2 to the 14^th week (W14), no active rTMS was used, and we observed a gradual rebound of FAA to its baseline value in both groups.